Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates Purchases 40,000 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) CFO James M. Frates acquired 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $2.53 per share, with a total value of $101,200.00. Following the completion of the acquisition, the chief financial officer now owns 233,464 shares in the company, valued at $590,663.92. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Amylyx Pharmaceuticals Price Performance

AMLX stock opened at $2.65 on Tuesday. Amylyx Pharmaceuticals, Inc. has a 1 year low of $1.58 and a 1 year high of $19.95. The company has a market cap of $180.22 million, a P/E ratio of -2.48 and a beta of -0.62. The stock’s fifty day moving average price is $2.14 and its 200-day moving average price is $2.72.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last announced its earnings results on Thursday, August 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.35). The firm had revenue of ($1.02) million during the quarter, compared to analysts’ expectations of $18.83 million. Amylyx Pharmaceuticals had a negative return on equity of 15.51% and a negative net margin of 17.86%. During the same period in the previous year, the business posted $0.31 earnings per share. As a group, analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.27 earnings per share for the current year.

Hedge Funds Weigh In On Amylyx Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in AMLX. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Amylyx Pharmaceuticals in the 2nd quarter worth $156,000. Maven Securities LTD increased its position in Amylyx Pharmaceuticals by 300.0% in the second quarter. Maven Securities LTD now owns 100,000 shares of the company’s stock worth $190,000 after buying an additional 75,000 shares in the last quarter. Algert Global LLC purchased a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at about $47,000. Almitas Capital LLC bought a new position in shares of Amylyx Pharmaceuticals during the 2nd quarter valued at approximately $3,617,000. Finally, AQR Capital Management LLC increased its holdings in Amylyx Pharmaceuticals by 2,768.0% in the 2nd quarter. AQR Capital Management LLC now owns 3,340,943 shares of the company’s stock worth $6,348,000 after acquiring an additional 3,224,454 shares in the last quarter. Hedge funds and other institutional investors own 95.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. The Goldman Sachs Group lifted their target price on Amylyx Pharmaceuticals from $3.00 to $4.00 and gave the stock a “neutral” rating in a report on Friday, July 12th. HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, July 10th. Six analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $17.60.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.